Liquidia Technologies Inc. (NASDAQ:LQDA) and ARCA biopharma Inc. (NASDAQ:ABIO) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia Technologies Inc.	2.71M	75.16	53.14M	-2.25	0.00
ARCA biopharma Inc.	N/A	0.00	7.93M	-0.82	0.00

Table 1 demonstrates Liquidia Technologies Inc. and ARCA biopharma Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Liquidia Technologies Inc. and ARCA biopharma Inc.

	Net Margins	Return on Equity	Return on Assets
Liquidia Technologies Inc.	-1,960.89%	-813.3%	-135.7%
ARCA biopharma Inc.	0.00%	0%	0%

Liquidity

4.9 and 4.9 are the respective Current Ratio and a Quick Ratio of Liquidia Technologies Inc. Its rival ARCA biopharma Inc.’s Current and Quick Ratios are 8.5 and 8.5 respectively. ARCA biopharma Inc. has a better chance of clearing its pay short and long-term debts than Liquidia Technologies Inc.

Insider & Institutional Ownership

Liquidia Technologies Inc. and ARCA biopharma Inc. has shares held by institutional investors as follows: 53.1% and 15.4%. Insiders held roughly 1.7% of Liquidia Technologies Inc.’s shares. Competitively, insiders own roughly 0.89% of ARCA biopharma Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Liquidia Technologies Inc.	-10.3%	20.99%	-23.61%	9.36%	0%	-19.62%
ARCA biopharma Inc.	5.75%	9.55%	-15.6%	-24.74%	-36.11%	37.93%

For the past year Liquidia Technologies Inc. had bearish trend while ARCA biopharma Inc. had bullish trend.

Summary

ARCA biopharma Inc. beats on 7 of the 9 factors Liquidia Technologies Inc.

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.